Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cytek Biosciences, Inc. Market Cap
The Cytek Biosciences, Inc. (CTKB) share price is expected to increase by 77.19% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered CTKB. Price targets range from $7 at the low end to $12 at the high end. The current analyst consensus for CTKB is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
CTKB is a stock in Health Care which has been forecasted to be worth $8.7 as an average. On the higher end, the forecast price is $12 USD by from Goldman Sachs and on the lower end CTKB is forecasted to be $7 by Tejas Savant from Morgan Stanley.
These are the latest 20 analyst ratings of CTKB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Westenberg Piper Sandler | Overweight | $8 | Maintains | Aug 13, 2024 |
| David Westenberg Piper Sandler | Overweight | $8.5 | Maintains | May 13, 2024 |
| David Westenberg Piper Sandler | Overweight | $10 | Maintains | Mar 6, 2024 |
| Matthew Sykes Goldman Sachs | Buy | $10 | Maintains | Feb 29, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $9 | Initiates | Dec 14, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $7 | Maintains | Nov 9, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $8 | Maintains | Oct 24, 2023 |
| David Westenberg Piper Sandler | Overweight | $10 | Maintains | Oct 16, 2023 |
| Andrew Cooper Raymond James | Market Perform | Initiates | Jul 19, 2023 | |
| Tejas Savant Morgan Stanley | Equal-Weight | $13 | Maintains | May 11, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $12 | Maintains | May 10, 2023 |
| David Westenberg Piper Sandler | Overweight | $15 | Maintains | Mar 7, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $14 | Maintains | Mar 2, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $14 | Maintains | Mar 2, 2023 |
| David Westenberg Piper Sandler | Overweight | $16 | Maintains | Aug 18, 2022 |
| Tejas Savant Morgan Stanley | Equal-Weight | $15 | Maintains | Aug 12, 2022 |
| Matthew Sykes Goldman Sachs | Buy | $17 | Maintains | Aug 11, 2022 |
| Matthew Sykes Goldman Sachs | Buy | $15 | Maintains | Jul 14, 2022 |
| David Westenberg Piper Sandler | Overweight | $12 | Maintains | May 16, 2022 |
| Tejas Savant Morgan Stanley | Equal-Weight | $11 | Maintains | May 13, 2022 |
When did it IPO
2021
Staff Count
645
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Wenbin Jiang Ph.D.
Market Cap
$737.7M
In 2023, CTKB generated $193.0M in revenue, which was a increase of 17.67% from the previous year. This can be seen as a signal that CTKB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality Management System (QMS) certification.
Sun, 11 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Tue, 06 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.
Mon, 24 Jun 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Thu, 30 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
